Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.49 |
| ▸ | DPP4 | P27487 | 5/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706661 | 1.00 | DPP7 (0.49) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL1189924 | 1.00 | DPP7 (0.49) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL6824220 | 0.98 | DPP7 (0.48) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL14148845 | 0.91 | — | — | |
| Trifluoroacetic Acid SCHEMBL6824315 | 0.86 | DPP8 (0.48) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL14024791 | 0.83 | DPP4 (0.51) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL30484009 | 0.83 | HTR1A (0.46) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL6484035 | 0.82 | CYP3A4 (0.49) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL10076132 | 0.82 | CYP3A4 (0.49) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL6824681 | 0.82 | DPP4 (0.50) | DPP7DPP4DPP8FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2440558-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2010144486-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144486-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | DPP7 1510/4885DPP4 1968/4885DPP8 3001/4885 |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | DPP7 1377/4885DPP4 1869/4885DPP8 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.